Introduction
'First generation' applications of gene therapy have not generally required regulation, either because expression is short-term (cancer therapy) or because they involve proteins with very large therapeutic indices (such as adenosine deaminase, CFTR and coagulation factors VIII and IX). While these applications are natural first choices for the field, they represent only a small part of the clinical potential of gene therapy. Most diseases are heterogeneous and dynamic in nature, and most proteins have limited therapeutic windows. For gene therapy to achieve its full potential as a broadly applicable platform for safe and effective protein delivery, pharmacological control over the level of expression is likely to be critical.
The case for regulation is illustrated in Figure 1 , which depicts hypothetical plasma levels of a secreted therapeutic protein delivered in three alternative ways. Injection of the recombinant protein ( Figure 1a ) leads to large fluctuations in serum levels with kinetics dependent on the intrinsic pharmacokinetics of the protein; levels are only transiently within the therapeutic window, mainly residing above it (potentially unsafe) or below it (nonefficacious). Gene therapy offers the promise of replacing unpleasant frequent injections of an expensively manufactured protein with an infrequent or even one-time administration of vector, which would then provide continuous protein production and consequently steady, therapeutic protein levels ( Figure 1b) . However, without a way to control expression of the gene, protein levels might stabilize at sub-or super-therapeutic levels -irreversibly. Placing expression of the gene under drug control (Figure 1c ) allows titration into the therapeutic window, allows dosing to be adjusted as the disease evolves, and (crucially) allows therapy to be terminated by drug withdrawal.
At what point might regulation systems become routinely employed in gene therapy applications? Most likely, clinical and/or commercial success with delivery of a secreted protein by constitutive gene therapy will lead to broader acceptance of the technique as a delivery route. This may well coincide with the emergence from development of numerous genomics-derived secreted proteins, increasing the demand for more efficient and generic delivery options. If regulation systems have by then been clinically proven to be safe and effective, regulated gene therapy will be poised to become widely adopted, and as experience accumulates, the enhanced safety of the approach might render unregulated therapies increasingly unacceptable. Thus although regulation presupposes success in developing delivery vehicles, it could very rapidly assume a major role once the first few gene therapy products are approved. Developing regulation systems is an investment for a future that may not be far away.
Drug-regulated transcription systems
One simple way to regulate expression of a transgene is to equip it with a known promoter that is sensitive to a physiological signal, such as glucose elevation or hypoxia.
1 Such 'endogenous' control systems may prove useful in some applications, such as glucose-responsive control of insulin production. However, true physiologically responsive regulation has proved difficult to achieve, and ultimately these systems offer a largely qualitative level of control -the clinician still relinquishes control of the absolute level of gene expression upon gene administration, and cannot shut off expression at will. More progress has instead been made on exogenous control systems, in which gene expression is controlled pharmacologically by administering a small molecule drug.
An appropriate pharmacological regulation system should have several key features. 2 Basal expression should be very low, and be inducible to high levels over a wide enough dose range to provide useful dose-responsive control (ie the system should resemble a rheostat rather than an on-off switch). Induction should be a posi- tive effect (adding rather than removing a drug), and use an orally active small molecule that has no pleiotropic effects in mammalian cells. The regulatory protein(s) should also have no effects on endogenous gene expression, and ideally should be human in origin to minimize potential immunogenicity. To date, efforts have focused on regulation at the level of transcription, although new approaches are emerging (see later). Four
Gene Therapy major systems are currently under development: those regulated by the antibiotic tetracycline (Tet), 3 ,4 the insect steroid ecdysone or its analogs, 5 the antiprogestin mifepristone (RU486), 6 and chemical 'dimerizers' such as the immunosuppressant rapamycin and its analogs. [7] [8] [9] [10] They all involve the drug-dependent recruitment of a transcriptional activation domain to a basal promoter driving the gene of interest, but differ in the mechanism of recruitment (for a review see Ref.
2).
The Tet system was the first described and has become well established as a research tool. The natural Tetcontrolled DNA binding domain (DBD) of the E. coli Tet repressor (TetR) is fused to a heterologous transcriptional activation domain (AD), usually herpes virus VP16; transcription of genes equipped with a minimal promoter and upstream TetR binding sequences can then be controlled by Tet, or analogs such as doxycycline. The original Tet-off system, 3 in which the drug de-activates expression, is being superceded by the positively controlled Tet-on system. 4 Similar principles underlie the ecdysone (Ec) system, in which the natural Ec-dependent DBD from the Drosophila Ec receptor is coupled to VP16; the protein is co-expressed with another steroid receptor (RXR) to obtain Ec-activated transcription. 5 In the mifepristone system, drug-regulated transcription is achieved by fusing heterologous DBD (yeast GAL4) and AD (VP16) proteins to a mutant human progesterone receptor that is unaffected by endogenous hormones but is activated by synthetic antiprogestins, at doses sufficiently low to avoid side-effects in humans. 6 While these first three systems rely on allosteric control, dimerizer controlled transcription uses the principle of induced proximity. 2, 11 Heterologous DBDs and ADs are each fused to a drug-binding domain, rendering transcription dependent on a bivalent drug that can crosslink the two proteins and reconstitute an active transcription factor. Homodimeric drugs can be used, 8, 9 but most current focus is on the heterodimerizer rapamycin, 7 which binds to the human proteins FKBP and FRAP. In this system, a human chimeric DBD called ZFHD1 12 is joined to FKBP and the human NF-B p65 AD (which was found to out-perform VP16 7 ) is fused to FRAP. Addition of rapamycin dimerizes the two fusion proteins and activates transcription of genes downstream of ZFHD1 binding sites. Because rapamycin itself is immunosuppressive, the system has been modified to function with nonimmunosuppressive analogs ('rapalogs'), by incorporating mutation(s) in the FRAP domain that accommodate modified drugs. 13, 14 All of these systems basically work. In each case the initial papers demonstrate low basal levels and highly inducible gene expression in cell lines, and all use orally bioavailable and broadly inert drugs. How far away are they from clinical reality?
Animal models of regulated gene therapy
Most of these regulation systems were actually developed largely for use in research, in particular for generating conditional alleles in transgenic mice. 11 These uses are very important, and indeed can have direct application to gene therapy: for example, generation of producer cell lines for viral vectors in which toxic gene products must be expressed. However, they are much less challenging than real-world gene therapy appli-cations, where one does not have the luxury of sifting through clones to identify a well-behaved, highly inducible cell line. Hence a very important advance in the last 2 years has been the testing of regulation systems using bona fide gene transfer protocols in animal models. These studies, driven in part by the parallel development of vector systems suitable for long-term expression, have moved the field considerably closer to the clinic, while highlighting the key issues that remain for each system and for regulated gene delivery in general.
A convenient target gene for such experiments is that for erythropoietin (Epo), which provokes an easily assayed phenotypic change (hematocrit elevation) and also provides a stringent test for basal, uninduced expression levels due to its extraordinary potency. Early work demonstrated Tet-regulated delivery of Epo from myoblasts engineered by ex vivo retroviral transduction and then transplanted into mouse muscle, using the Tetoff 15 or Tet-on 16 systems. Primary myogenic cells were transduced with two retroviruses, one encoding the transcription factors under a muscle-specific promoter and the other the target gene. Epo production could be cycled on and off through a 70-fold net induction over a 5-month period by provision of doxycycline in drinking water, with concomitant reversible changes in hematocrit. Importantly, there was no apparent immune response to the VP16 and TetR proteins. 16 However, a notable observation with these studies was the significant basal expression of Epo in the absence of the inducing drug or of the regulatory protein. Delivery of Tet-on regulated Epo has also been achieved using electroporation-enhanced direct transfer of naked plasmid DNA, with similar observations, 17 and the Tet system has been delivered in vivo using other vectors such as HSV. 18 The properties of the mifepristone-regulated system have been investigated by incorporating it into a recombinant adenovirus with a human growth hormone (hGH) target gene and injecting i.v. into mice, leading to liver transduction. 19 This work included several innovations, including partial humanization of the regulatory transcription factor by substituting p65 7 for VP16, driving expression of the regulatory transcription factor from a liver-specific promoter, and incorporation of a chromosomal insulator sequence in an attempt to minimize uninduced transcription levels. Background transcription was indeed undetectable in vitro and in vivo. Over 50 days, hGH production could be cycled on and off three times, or maintained at steady state levels, by delivery of inducer through i.p. or p.o. pulses or through a slowrelease pellet, in the latter case resulting in accelerated weight gain of the animals.
More recently, adeno-associated virus (AAV) has emerged as a very promising vector for long-term transgene expression, particularly when administered intramuscularly. Several groups have examined the feasibility of regulated delivery of murine Epo (mEpo) from intramuscularly administered AAV vectors. Co-delivery of an Epo target gene and the Tet-off regulatory system on two AAV vectors allowed reversible control of Epo levels and hematocrit over an 18-week period in immunocompetent mice. 20 Similar results were recently reported with the more clinically relevant Tet-on system using a single AAV vector containing both genes. 21 In both these studies Epo expression, and as a result hematocrit, was reversibly induced up to three times over a 4-7-month period.
However, significant basal elevation of hematocrit was again observed in the absence of deliberate induction. Where investigated, 20 no immune response to the nonmurine transgenes was detected.
The two-vector approach has also been used to deliver the rapamycin-regulated system to immunocompetent mouse muscle for the control of hGH 22 or mEpo production. 23 Injection of adenoviral or AAV vectors i.m. allowed stable and reproducible rapamycin inductions of hGH, in the case of AAV vectors for at least a year. 22 Precise fluctuations in Epo level and duration of response, including steady state levels, could be obtained by varying the frequency and level of dosing for at least 6 months. 23 No elevations of the hematocrit or of Epo levels were observed over a 2-month period in the absence of rapamycin, indicating negligible basal expression. 23 A major recent advance has been the first introduction of a regulated gene therapy system into primates. 23 A two-AAV vector system encoding rapamycin-regulated rhesus Epo was introduced i.m. into a rhesus monkey. No changes in Epo levels or hematocrit were seen up to 1 month, but dosing with rapamycin permitted Epo to be cycled on and off twice over 3 months, elevating hematocrit. Interestingly, subsequent doses failed to provoke an induction, in marked contrast to the analogous mouse experiments. 23 However in other similar monkeys inducibility persists for more than a year (JM Wilson et al, unpublished observations), suggesting that monkeyspecific promoter or immune effects may be responsible.
These recent results clearly demonstrate the ability of regulation systems to provide long-term precise control of transgene expression, and provide a glimpse of the therapeutic potential. The challenge for the next few years is to convert this promise into clinical validation. With our recent experience in hand, what are the key issues that will need to be confronted?
Optimizing components for clinical application
One important task is simply to ensure that all transcriptional components are fully optimized for clinical use. There is particular scope for improving activation domains (ADs), whose potencies directly dictate the maximum levels of protein produced. New strategies for engineering ADs that increase potency without apparent cellular toxicity will be valuable. 24 ADs might also be optimized specifically for activity in muscle or other target tissues. For some systems, delivery in a single AAV vector will require reducing the size of regulatory proteins and associated DNA sequences (promoters, internal ribosome entry sequence (IRES) motifs, etc). But perhaps the biggest challenge for most regulatory systems is humanizing them to minimize potential immunogenicity (see later).
The basal expression observed in some of the mouse studies is clearly cause for concern. A priori, such basal expression might be intrinsic to the target gene promoter (low-level regulation-independent transcription), and/or might arise from 'leakiness' of the regulatory transcription factor (residual activation in the absence of inducer). Studies of the Tet system in mice show evidence for both of these phenomena, 16, 20, 21 whereas no background was observed with the mifepristone 19 or rapamycin sys-tems, 22, 23 although direct comparisons are complicated by differences in vector, dose and target gene. Eliminating background due to target gene construction should be straightforward, and may be as simple as replacing the minimal CMV promoter typically used for Tet target genes [15] [16] [17] [18] 20, 21 with weaker basal promoters. 19, 22, 23 For any of the systems, installing insulator sequences 19 or simply reducing vector dose 17, 20, 21 should also help. Eliminating intrinsic leakiness of the regulatory transcription factor would require more extensive work.
When finalizing regulation systems for clinical use, testing in higher mammals will be critical. It is becoming apparent that results obtained using inbred strains of laboratory mice will not necessarily scale up to larger and more heterogeneous species (such as humans). For example, intramuscular administration of rapamycinregulated AAV vectors provides regulated mEpo production for the lifetime of experimental mice, yet in some rhesus monkeys expression of rhEpo can only be cycled twice before expression is extinguished. 23 Transcription factor potency and immunogenicity (see below), promoter strength and stability, and drug pharmacokinetics and pharmacodynamics (as well as the behavior of the delivery vector) are all likely to vary significantly between species, making preclinical characterization in non-human primates particularly valuable.
Chemistry
As clinical applications approach, there will be a key role for synthetic chemistry in optimizing the pharmacology of the inducing drugs, and engineering out undesirable activities. In some cases this will involve simultaneous modification of the transcription factor. For example, a mutation has been designed into the FRAP-AD fusion protein that allows the rapamycin system to be activated by a diverse set of non-immunosuppressive analogs, 14 as well as rapamycin itself. 22, 23 Similar strategies could be useful with tetracycline analogs 25 to create a system that would not be activated by tetracyclines prescribed as Gene Therapy antibiotics or present in foodstuffs, or with the mifepristone system to ensure safety. With a diverse set of potent and inert drug candidates in hand, the optimal inducer can then be selected for each application: different target genes may require drugs with different half-lives, to match the desired kinetics of the protein delivery event.
Minimizing immunogenicity
Because current regulatory systems involve constitutive and long-term intracellular expression of at least one chimeric regulatory protein, often of foreign origin, immune recognition of transduced cells is an important concern. At present there are insufficient data to know whether current systems will be immunogenic in humans. In mice, engineered myoblasts 16 or AAV-transduced muscle 20 expressing Tet system components elicited no detectable immune response. However, in an unrelated clinical trial, T cell expressing a fusion protein of bacterial and herpes virus origin (Hy-TK) were recognized and eliminated even in immune-deficient HIV patients. 26 Notwithstanding differences in target tissue and vector, this study emphasizes that immune recognition is a legitimate possibility, and it seems prudent to mitigate the risk by building regulatory systems using human proteins.
The most difficult challenge is to identify a DNA binding domain (DBD) that is of human origin, which will nevertheless not activate any endogenous human genes, and whose target sites will not be recognized by any endogenous human transcription factors. For the rapamycin system the solution was to use ZFHD1, a chimera of two human DNA-binding subdomains that together bind a unique composite site. 12 Using this and the p65 AD allowed the rapamycin system to be built exclusively from human proteins. The mifepristone system might be 'humanized' by replacing the yeast GAL4 DBD with ZFHD1; but the Tet and ecdysone systems cannot, since the foreign DBD is required to confer drug binding. Even for completely human systems, the theoretical potential remains for immune recognition of junction peptides between domains, and peptides encompassing the point mutations engineered to accommodate drug analogs. Such sequences could be further tailored to minimize their recognition by common human MHC haplotypes.
Looking into the future, immunogenicity might eventually be bypassed by dispensing with regulatory proteins altogether. For example, the logical extrapolation of dimerizer regulation is control using a bifunctional small molecule, one end of which sequence specifically binds DNA, with the other mimicking an activation domain or recruiting an endogenous one. Simple molecules that specifically bind DNA 27 or mimic activation domains 28 are already known. Alternatively, regulating expression at the level of translation using drugs that bind RNA 29 might eventually offer a way to confer regulation without expression of regulatory proteins.
Getting the kinetics right
Effective delivery of a secreted protein using gene therapy will likely require the natural kinetics of expression to be mimicked. Transcriptional regulatory systems provide induction/decay kinetics on a time scale of days, reflecting the early point of regulation and the many potentially rate-limiting steps between transcription and protein production (Figure 2 ). Such prolonged kinetics are appropriate for many secreted proteins (such as Epo) that regulate growth and differentiation events. However many proteins are naturally secreted with much faster kinetics: for example insulin, which is secreted post-prandially in a brief 4-h pulse. If regulated gene therapy is to be used to deliver such proteins, new technologies will likely be required.
Regulating the translation step 29 might offer faster kinetics. However, nature's solution to rapid protein production is to regulate the very last step -secretion itself. A new technology mimics this strategy to provide rapid, pulsatile protein release 30 ( Figure 2 ). Proteins are made constitutively, but engineered to accumulate in the endoplasmic reticulum until the addition of a small molecule ligand, which releases the stored protein to be processed and secreted. Pulsed delivery of insulin with this system has been used to correct hyperglycemia in mice. Such new technologies should allow a much broader spectrum of secreted proteins to be delivered with appropriate kinetics using regulated gene therapy.
Conclusions
Drug-regulated gene expression has great potential for expanding the efficacy and safety of gene therapy; for many proteins it may be essential. Great strides have been made in refining regulated transcription systems for clinical use, and work has now progressed as far as primate models, with clinical trials of a regulated AAV system a near-term prospect. With a path to the clinic established and new technologies emerging, regulation is poised to take its place as a major area of development for the field of gene therapy.
